EcoR1 Capital LLC 13D and 13G filings for Neoleukin Therapeutics, Inc.:
- Schedule 13D must be filed within ten days after a person or an organization acquires beneficial ownership of more than 5% of a voting class of a company's equity securities.
- Shares have been adjusted for stock splits.
| Reported DateTime |
Transaction Date |
Type | Company Symbol |
Filed By Symbol |
Shares Owned % Owned |
Shares Vs. Prev Report | View |
| 2022-02-14 3:03 pm Sale |
2021-12-31 | 13G | Neoleukin Therapeutics, Inc. NLTX |
EcoR1 Capital LLC | 43,031 2.000% |
-113,104 (-72.44%) |
Filing |
| 2021-02-16 12:05 pm Sale |
2020-12-31 | 13G | Neoleukin Therapeutics, Inc. NLTX |
EcoR1 Capital LLC | 156,135 7.500% |
-39,659 (-20.26%) |
Filing |